Breeze Meds vs Wisp
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Breeze Meds
Best for compounded GLP-1 access with named prescribers and 4-pharmacy networkStarting at $199/mo
Wisp
Best for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-testedStarting at $225/mo
Side-by-Side Comparison
| Feature | Breeze Meds | Wisp |
|---|---|---|
| Overall Score | ✓7.3/10 | 7.0/10 |
| Starting Price | ✓$199/mo | $225/mo |
| Editorial Rating | ✓3.7 ★ /5 | 3.5 ★ /5 |
| Features | 6 features | 6 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Breeze Meds
Pros
- ✓Available in all 50 US states
- ✓LegitScript certified seal displayed in footer
- ✓Publicly named medical team with NPI numbers: Dr. Ana Lisa Carr MD (NPI 1689841744) and Dr. Kelly Tenbrink MD (NPI 1346482684)
- ✓Four named 503A pharmacy partners: Belmar Pharma Solutions, Strive Pharmacy, Epiq Scripts, Casa Pharma Rx
- ✓Both injectable and oral formats available for semaglutide and tirzepatide
- ✓No FDA warning letters or litigation on record as of 2026-04-09
Cons
- ✗Runs on the same Lion MD clinician network and the same 4 compounding pharmacies as Care Bare Rx and Synergy Rx — if you're comparing the three brands, be aware you're comparing three storefronts on top of one underlying operation, not three independent providers
- ✗Compounded medications are not FDA-approved
- ✗Compounded vs. brand-name drug sourcing is ambiguously disclosed on the product pages
- ✗Terms of Service page returns a 404 (Privacy Policy is present) — a procedural transparency gap
- ✗Insurance acceptance is not clearly disclosed beyond FSA/HSA eligibility
Wisp
Pros
- ✓Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
- ✓LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
- ✓Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing
Cons
- ✗EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
- ✗Pharmacy partners not publicly named
- ✗States served list not publicly enumerated
Our Verdict
Breeze Meds edges out Wisp with a higher overall score of 7.3/10 and is particularly strong for compounded GLP-1 access with named prescribers and 4-pharmacy network. Wisp remains a solid alternative, especially if you're looking for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.